Search hospitals > Iowa > West Des Moines

Wolfe Eye Clinic

Claim this profile
West Des Moines, Iowa 50266
Global Leader in Age-Related Macular Degeneration
Global Leader in Macular Degeneration
Conducts research for Diabetic Macular Edema
Conducts research for Retinal Disease
Conducts research for Retinal Degeneration
50 reported clinical trials
1 medical researcher
Photo of Wolfe Eye Clinic in West Des MoinesPhoto of Wolfe Eye Clinic in West Des MoinesPhoto of Wolfe Eye Clinic in West Des Moines

Summary

Wolfe Eye Clinic is a medical facility located in West Des Moines, Iowa. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Diabetic Macular Edema, Retinal Disease, Retinal Degeneration and other specialties. Wolfe Eye Clinic is involved with conducting 50 clinical trials across 43 conditions. There are 1 research doctors associated with this hospital, such as Derek Bitner, MD.

Area of expertise

1Age-Related Macular Degeneration
Global Leader
Wolfe Eye Clinic has run 26 trials for Age-Related Macular Degeneration. Some of their research focus areas include:
Stage I
CFI positive
Stage II
2Macular Degeneration
Global Leader
Wolfe Eye Clinic has run 18 trials for Macular Degeneration. Some of their research focus areas include:
Stage I
Stage II
CFI positive

Top PIs

Clinical Trials running at Wolfe Eye Clinic

Age-Related Macular Degeneration
Macular Degeneration
Lazy Eye
Choroidal Neovascularization
Retinal Degeneration
Retinal Disease
None
Choroidal neovascularization
Wet AMD
Diabetic Macular Edema
Image of trial facility.

PDS Implant with Ranibizumab

for Age-Related Macular Degeneration

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Recruiting2 awards Phase 33 criteria
Image of trial facility.

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Avacincaptad Pegol

for Macular Degeneration

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.
Recruiting1 award N/A3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Wolfe Eye Clinic?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security